Skip to Content

Join the 'Sonidegib' group to help and get support from people like you.

Sonidegib News

Do Rising Cancer Drug Prices Warrant Regulation?

Posted 1 Nov 2017 by Drugs.com

WEDNESDAY, Nov. 1, 2017 – Cancer drug prices in the United States keep rising steadily, a new study says. "Regardless of competition or supplemental indications, our study found that there is a steady increase in costs of patented anticancer drugs over time," wrote the researchers. They included Dan Greenberg, an associate professor at Ben-Gurion University of the Negev in Israel. "We believe that new regulations may be needed to prevent additional increases in drug costs after launch, especially since Medicare is legally prohibited from negotiating drug prices," the researchers said in a university news release. Greenberg and his research team from Israel and the United States monitored monthly prices of 24 injectable, patented cancer drugs approved by the U.S. Food and Drug Administration between 1996 and 2012. Prices were tracked for eight years on average. After adjusting for ... Read more

Related support groups: Cancer, Methotrexate, Fluorouracil, Gleevec, Colorectal Cancer, Xeloda, Tasigna, Sprycel, Hydroxyurea, Herceptin, Erivedge, Mercaptopurine, Hydrea, Cisplatin, Carboplatin, Cytoxan, Bendamustine, Capecitabine, Temodar, Cyclophosphamide

Many Cancer Patients Skimp on Treatment Due to Cost

Posted 24 Oct 2017 by Drugs.com

TUESDAY, Oct. 24, 2017 – The high cost of cancer care in the United States has led more than one-quarter of patients to cut back on some part of their treatment, a new survey reveals. Commissioned by the American Society of Clinical Oncology (ASCO), the report found that 27 percent of cancer survivors or close relatives of a cancer patient said they'd skipped doctor visits or taken other steps to reduce health costs. To save money, nearly one in 10 said they had avoided doctor appointments. Eight percent had refused treatment; postponed filling or not filled prescriptions; or skipped doses of prescribed medications. And 7 percent said they had cut pills in half, according to the survey of more than 4,000 adults. Such measures can jeopardize treatment success, ASCO says. "We should all be alarmed that Americans are potentially risking not only their health, but also their lives, due to ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Fluorouracil, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Anastrozole, Votrient, Letrozole, Tarceva

Alternative Medicine Alone as Cancer Treatment Linked to Lowered Survival

Posted 17 Aug 2017 by Drugs.com

THURSDAY, Aug. 17, 2017 – People who choose alternative medicine over traditional cancer treatments for curable cancers have a higher risk of dying early, researchers report. "We now have evidence to suggest that using alternative medicine in place of proven cancer therapies results in worse survival," said study lead author Dr. Skyler Johnson from Yale School of Medicine and Yale Cancer Center. "It is our hope that this information can be used by patients and physicians when discussing the impact of cancer treatment decisions on survival," Johnson said in a school news release. Steve Jobs, co-founder and former CEO of Apple, is likely the most famous person who initially chose alternative medicine as a sole treatment. He eventually turned back to conventional medicine when the alternative medicine treatment didn't keep his pancreatic cancer at bay. But at that point, the cancer had ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Lupron, Medroxyprogesterone, Tamoxifen, Fluorouracil, Arimidex, Lupron Depot, Femara, Anastrozole, Letrozole, Xeloda, Megestrol, Zoladex, Megace, Evista, Pancreatic Cancer, Hydroxyurea

Treatment Costs Can Be Another Blow to Cancer Patients

Posted 27 Jul 2017 by Drugs.com

THURSDAY, July 27, 2017 – The emotional and physical costs of cancer can be staggering. But the financial side of cancer is also a great burden, with many patients in the United States struggling to pay for treatment, new research reveals. "The current health law has greatly improved access to meaningful health coverage for cancer patients, survivors and all those with chronic diseases," Chris Hansen, president of the American Cancer Society Cancer Action Network, said in a network news release. "Yet costs remain a challenge for those facing cancer. Our country and our lawmakers should come together to find bipartisan solutions that begin to address patient costs without sacrificing the quality of coverage," he urged. Researchers surveyed financial navigators at 11 hospitals in nine states. Financial navigators – typically trained social workers or nurses – help cancer patients ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Breast Cancer, Lupron, Medroxyprogesterone, Prostate Cancer, Tamoxifen, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Anastrozole, Brain Tumor, Letrozole, Skin Cancer, Tarceva

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Prostate Cancer, Tamoxifen, Fluorouracil, Tretinoin, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Rituxan, Isotretinoin, Colorectal Cancer

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Fluorouracil, Tretinoin, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Rituxan, Isotretinoin, Colorectal Cancer, Anastrozole

FDA Approves Odomzo (sonidegib) for Locally Advanced Basal Cell Carcinoma

Posted 26 Jul 2015 by Drugs.com

July 24, 2015 – The U.S. Food and Drug Administration today approved Odomzo (sonidegib) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy. Skin cancer is the most common cancer and basal cell carcinoma accounts for approximately 80 percent of non-melanoma skin cancers. Basal cell carcinoma starts in the top layer of the skin (called the epidermis) and usually develops in areas that have been regularly exposed to the sun and other forms of ultraviolet radiation. According to the National Cancer Institute, the number of new cases of non-melanoma skin cancer appears to be increasing every year. Locally advanced basal cell skin cancer refers to basal cancers that have not spread to other parts of the body, but cannot be curatively treated with local treatments, ... Read more

Related support groups: Basal Cell Carcinoma, Skin Cancer, Sonidegib, Odomzo

New Skin Cancer Drug Odomzo Approved by FDA

Posted 26 Jul 2015 by Drugs.com

FRIDAY, July 24, 2015 – A new drug to treat the most common form of skin cancer has been approved by the U.S. Food and Drug Administration. Odomzo (sonidegib) was cleared to treat locally advanced basal cell carcinoma in patients who cannot undergo surgery or radiation therapy, or whose skin cancer has returned after surgery or radiation therapy. Skin cancer is the most common type of cancer, and basal cell carcinoma accounts for about 80 percent of non-melanoma skin cancers. Locally advanced basal cell skin cancer has not spread to other parts of the body, but cannot be cured with surgery or radiation. Odomzo is a once-a-day pill designed to suppress a molecular pathway that is active in basal cell cancers, according to the FDA. The drug's approval was based on a clinical trial that included 66 patients who took 200 milligrams (mg) of Odomzo a day and 128 patients who took 800 mg a ... Read more

Related support groups: Basal Cell Carcinoma, Skin Cancer, Sonidegib, Odomzo

Odomzo Approved for Recurring Basal Cell Carcinoma

Posted 26 Jul 2015 by Drugs.com

FRIDAY, July 24, 2015 – Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat basal cell carcinoma skin cancer that has returned despite surgery or radiation. The treatment is sanctioned for people who are not candidates for additional surgery or radiation. Basal cell carcinoma accounts for about 80 percent of skin cancers that are not melanoma, a more deadly form of the disease. Basal cell starts in the top layer of skin, usually in areas that are most exposed to the sun, the agency said Friday in a news release. The once-daily pill is designed to inhibit a process that promotes the growth of cancerous lesions. The drug's label includes a boxed warning that it may cause death or severe birth defects in a growing fetus. Women who may become pregnant should verify pregnancy status before taking the drug. And both males and females who take Odomzo are ... Read more

Related support groups: Basal Cell Carcinoma, Skin Cancer, Sonidegib, Odomzo

Ask a Question

Further Information

Related Condition Support Groups

Basal Cell Carcinoma

Related Drug Support Groups

Odomzo

Sonidegib Patient Information at Drugs.com